poisar

Stocks · News reference

BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo

BenzingaAug 6, 2026, 11:34 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 6, 2026, 11:34 AM
Checked
Aug 6, 2026, 11:34 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading